# Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2016

- Company: [Protalix BioTherapeutics, Inc.](/companies/plx.md) (CIK 1006281)
- Form: 10-Q
- Filed: 2016-11-09
- Accepted by EDGAR: Nov 9, 2016, 16:32 ET
- Period: 2016-09-30
- Accession: 0001144204-16-132819
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1006281/000114420416132819/v452109_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1006281/000114420416132819/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-01 to 2016-09-30 | $4.7m | us-gaap:Revenues |
| Revenue | 9 months, 2016-01-01 to 2016-09-30 | $7.1m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-07-01 to 2016-09-30 | $4.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2016-01-01 to 2016-09-30 | $6.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-07-01 to 2016-09-30 | $422.0k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-01-01 to 2016-09-30 | $672.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2016-07-01 to 2016-09-30 | $6.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-01-01 to 2016-09-30 | $23.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-07-01 to 2016-09-30 | $2.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-01 to 2016-09-30 | $6.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-07-01 to 2016-09-30 | −$6.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-09-30 | −$24.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | −$7.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | −$26.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | −$0.27 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2016-01-01 to 2016-09-30 | −$24.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2016-01-01 to 2016-09-30 | $732.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-09-30 | $51.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $59.6m | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $70.5m | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $10.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $85.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-09-30 | −$15.1m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1006281/000114420416132819/v452109_10q.htm

Filed Nov 9, 2016.
Source: SEC EDGAR, the filing index for accession 0001144204-16-132819. Last ingested by Listed: Nov 10, 2026, 16:48 ET. No prices; not investment advice.
